All News
Big Advances for Two Osteoporosis Drugs
New developments with the FDA and new scientific findings are adding momentum to two drugs experts believe are game-changers in osteoporosis treatment.
Read ArticleIL-1 Suppression May Improve Dilated Cardiomyopathy
Interleukin-1 (IL-1) suppression helped reverse symptoms of dilated cardiomyopathy (DCM) for one patient in a case study that may implicate inflammation in the development of the condition.
Read ArticleThe Lung in RA: Little Progress
The progress that has been seen in the management of many aspects of rheumatoid arthritis (RA) has not been paralleled for the pulmonary disease that remains the second most common cause of death among these patients, an Australian expert reported here at the annual meeting of the Florida Society
Read ArticleThe RheumNow Week in Review –Fateful Outcomes in Rheumatology (7.13.18)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. Fateful outcomes in Rheumatology, what happens to Seronegatives, IL-23 fails, MRI progression, Not all inflammatory back pain becomes SpA:
Read ArticleNailfold Capillary Density Predicts Dermatomyositis Lung Involvement
In patients with juvenile dermatomyositis (DM), an association was seen between low nailfold capillary density and pulmonary involvement, European researchers reported.
Read ArticleObesity, Hypertension and Diuretics Drive Gout Risk
A recent metanalysis suggests that obesity, hypertension and diuretic use are associated with a two-fold increased risk of incident gout.
From a potential of 9923 articles, researchers analyzed 11 studies with data suitable for the meta-analysis.
Read ArticlePublic Citizen Pressures FDA to Pull Febuxostat
Public Citizen has petitioned the U.S. Food and Drug Administration (FDA) to remove Takeda's drug febuxostat (Uloric) from the market, citing the FDA's own warnings and evidence of serious cardiovascular harms. This follows on a recent FDA safety warning and NEJM paper citing cardiovascular concerns over febuxostat.
Read ArticleCardiovascular Risk Factors in Psoriasis, PsA and Seronegative SpA
Not a surprise to anyone anymore, increased risk of cardiovascular disease poses a danger of significant morbidity and mortality in patients underlying inflammatory arthritides.
Read ArticleSPAR Predicts ILD Progression in Systemic Sclerosis
The development and progression of interstitial lung disease in systemic sclerosis can be an ominous finding.
Read ArticleThe RheumNow Week in Review – Modifiable Behavior (5.18.18)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. He discusses opioids, new approval for polyarticular JIA, running and osteoarthritis, and modifiable behaviors that influence outcomes.
Read ArticleThe Hazardous Highs and Lows of Uric Acid
Both high and low levels of uric acid were linked with increased risks of death, showing a U-shaped association between serum uric acid levels and all-cause, cardiovascular, and cancer mortality, Korean researchers reported.
Read ArticleMortality Predictors in Rheumatoid Arthritis
A population based study from southern Denmark finds excess mortality RF-positive males with rheumatoid arthritis (RA) and that employment status and comorbidity were independent predictors of mortality.
Read ArticleMortality Risks Shift in Granulomatosis with Polyangiitis
Mortality remains high in granulomatosis with polyangiitis (GPA), but the causes of death tend to change over time, a researcher reported here.
Read ArticleThe RheumNow Week in Review – Why Comorbidity is Like the Weather (5.3.18)
Dr. Jack Cush discusses the news and journal articles from the past week on RheumNow.com.
Read ArticleFDA Advisors Weigh COX-2 Inhibitor Safety
Should celecoxib (Celebrex) be officially declared as no riskier for the heart than other non-steroidal anti-inflammatory drugs (NSAIDs) naproxen and ibuprofen, and do those other NSAIDs interfere with aspirin for cardiovascular prevention?
Read ArticleFDA Review: Take Two for Baricitinib
FDA staff remain worried about the safety of baricitinib, an oral JAK inhibitor intended for treatment of rheumatoid arthritis, according to briefing documents prepared for an advisory committee meeting on Monday.
Read ArticleTobacco Associated Deaths in the USA
JAMA Internal Medicine reports that in the USA, those who smoke cigar, pipe, or cigarette have a significant overall mortality risk, and a much highers cancer mortality risk compared to nonsmokers.
Read ArticleIncreased Comorbidity Burden in Lupus African Americans
Researchers from Vanderbilt University Medical Center used electronic health records (EHR) to perform a phenome-wide study comparing African American (AA-SLE) and Caucasian (C-SLE) with systemic lupus erythematosus (SLE) and found more comorbidities in AA-SLE, especially renal, cardiovascular, an
Read ArticleRituximab May Halt ILD in Antisynthetase Syndrome Myositis
A multicenter study assessed patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) and found that rituximab (RTX) therapy was associated with either improved or stable pulmonary outcomes in most.
Read ArticleThe RheumNow Week in Review -30 March 2018
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on drug regulatory decisions, fenofibrate and gout, Still's disease, TB and infection rates, SpA and hidradenitis suppurativa, and predicting methotrexate non-responders.
Read Article